NVIDIA was founded in 1993 when Jensen Huang, Chris Malachowsky, and Curtis Priem met at a Denny’s restaurant near San Jose. With just $40,000 in starting capital, they sketched out their vision for the company over diner food. In its early days, the silicon chip industry was laboratory-based, empirical-based. Since then, the industry has shifted…
Helix and Recursion join forces in quest to crack the AI-driven drug discovery code
The UK Biobank, with genetic data on half a million individuals, set a benchmark for scale in medical research. It contains whole genome sequencing data for all 500,000 participants, making it the world’s largest genetic project to date. A recent collaboration between the San Diego–headquartered clinico-genomics company Helix and the Salt Lake City–based biotech Recursion…
Unleashing a new frontier: The power of germline clinico-genomic data to drive therapeutic development
Over the past decade, the use of deeper sources of real-world data across all stages of the drug development life cycle has become increasingly important to guide disease understanding, trial designs, clinical guidelines, regulatory submissions and post-market studies. The advent of these deeper sources was prompted by the HITECH Act, which had the effect of…